Abstract
To conclude, this chapter entertains some ideas about melatonin’s potential as a nutraceutical agent. Much work must be done to transform this potential into a reality.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of a health claim related to melatonin and reduction of sleep onset latency (ID 1698; 1780, 4080) pursuant to Article 13 of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2241.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to melatonin and alleviation of subjective feelings of jet lag (ID 1953), and reduction of sleep onset latency, and improvement of sleep quality (ID 1953) pursuant to Article 13 of Regulation (EC) No 1924/20061. EFSA J., 2010, 8, 1461. EFSA J 2010;8,1461.
Tan DX, Zanghi BM, Manchester LC, Reiter RJ. Melatonin identified in meats and other food stuffs: potentially nutritional impact. J Pineal Res. 2014;57(2):213–8.
Erland LA, Murch SJ, Reiter RJ, Saxena PK. A new balancing act: the many roles of melatonin and serotonin in plant growth and development. Plant Signal Behav. 2015;10:e1096469.
Arnao MB, Hernandez-Ruiz J. Functions of melatonin in plants: a review. J Pineal Res. 2015;59:133–50.
Iriti M, Varoni EM, Vitalini S. Melatonin in traditional Mediterranean diets. J Pineal Res. 2010;49:101–5.
Iriti M, Varoni EM. Melatonin in Mediterranean diet, a new perspective. J Sci Food Agric. 2015;95:2355–9.
Kennaway DJ: Are the proposed benefits of melatonin-rich foods too hard to swallow? Crit Rev Food Sci Nutr 2015;0.
Iriti M, Varoni EM. Commentary: are the proposed benefits of melatonin-rich foods too hard to swallow? Front Nutr. 2016;3:2.
Fulia F, Gitto E, Cuzzocrea S, Reiter RJ, Dugo L, Gitto P, Barberi S, Cordaro S, Barberi I. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001;31:343–9.
Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, Cordaro S, Corona G, Trimarchi G, Barberi I. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50:756–60.
Gitto E, Romeo C, Reiter RJ, Impellizzeri P, Pesce S, Basile M, Antonuccio P, Trimarchi G, Gentile C, Barberi I, Zuccarello B. Melatonin reduces oxidative stress in surgical neonates. J Pediatr Surg. 2004;39:184–9.
Gitto E, Reiter RJ, Sabatino G, Buonocore G, Romeo C, Gitto P, Bugge C, Trimarchi G, Barberi I. Correlation among cytokines, bronchopulmonary dysplasia and modality of ventilation in preterm newborns: improvement with melatonin treatment. J Pineal Res. 2005;39:287–93.
Nordlund JJ, Lerner AB. The effects of oral melatonin on skin color and on the release of pituitary hormones. J Clin Endocrinol Metab. 1977;45:768–74.
Barchas J, DaCosta F, Spector S. Acute pharmacology of melatonin. Nature. 1967;214:919–20.
Jahnke G, Marr M, Myers C, Wilson R, Travlos G, Price C. Maternal and developmental toxicity evaluation of melatonin administered orally to pregnant Sprague-Dawley rats. Toxicol Sci. 1999;50:271–9.
Anton-Tay F, Diaz JL, Fernandez-Guardiola A. On the effect of melatonin upon human brain. Its possible therapeutic implications. Life Sci I. 1971;10:841–50.
Jacob S, Poeggeler B, Weishaupt JH, Siren AL, Hardeland R, Bahr M, Ehrenreich H. Melatonin as a candidate compound for neuroprotection in amyotrophic lateral sclerosis (ALS): high tolerability of daily oral melatonin administration in ALS patients. J Pineal Res. 2002;33:186–7.
Weishaupt JH, Bartels C, Polking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Huther G, Schneider A, Bach A, Siren AL, Hardeland R, Bahr M, Nave KA, Ehrenreich H. Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res. 2006;41:313–23.
Chahbouni M, Escames G, Lopez LC, Sevilla B, Doerrier C, Munoz-Hoyos A, Molina-Carballo A, Acuna-Castroviejo D. Melatonin treatment counteracts the hyperoxidative status in erythrocytes of patients suffering from Duchenne muscular dystrophy. Clin Biochem. 2011;44:853–8.
Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep laboratory investigations on hypnotic properties of melatonin. Psychopharmacology (Berl). 1990;100:222–6.
Silman RE. Melatonin: a contraceptive for the nineties. Eur J Obstet Gynecol Reprod Biol. 1993;49:3–9.
Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, Pelzl le H, Gotthardt DN, Cekauskas A, Manikas M, Mikalauskas S, Mikalauskene L, Bruns H, Zorn M, Weigand MA, Buchler MW, Schemmer P. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res. 2011;50:381–8.
Galley HF, Lowes DA, Allen L, Cameron G, Aucott LS, Webster NR. Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis. J Pineal Res. 2014;56:427–38.
Andersen LP, Werner MU, Rosenkilde MM, Fenger AQ, Petersen MC, Rosenberg J, Gogenur I. Pharmacokinetics of high-dose intravenous melatonin in humans. J Clin Pharmacol. 2016;56:324–9.
Bondi CD, Khainar R, Karnal KM, Witt-Enderby P. An early development budget impact model for the use of melatonin in the treatment and prevention of osteoporosis. Clin Pharmacol Biopharm. 2015;4:132. doi:10.4172/2167-065X.1000132.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Cardinali, D.P. (2016). Melatonin as a Nutraceutical. In: Ma Vie en Noir. Springer Biographies. Springer, Cham. https://doi.org/10.1007/978-3-319-41679-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-41679-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-41678-6
Online ISBN: 978-3-319-41679-3
eBook Packages: MedicineMedicine (R0)